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The advent of the single-molecule myosin motility assay has provided important biophysical data regarding myosin function and the nature of myosin-actin interaction at the single-molecule level (6, 42) . These studies reveal that the unitary properties of the myosin "power stroke" generates 5-10 pN of force over a 5-to 15-nm power stroke (7) . Moreover, these studies have revealed that the monomeric myosin molecule retains motor function compared with the dimeric myosin molecule (21, 28, 37) , although both heads may be required for optimal motor function (2, 3, 15, 16) . A limitation of single-molecule studies is that they do not provide direct insight into myosin motor function in the context of an intact three-dimensional contractile system under physiological conditions. In nature, individual myosin motors operate within vast assemblies of motors contained within the lattice structure of the intact sarcomere. As a consequence, the summation of motor protein unitary output to power muscle motility and movement is complicated by a number of factors including sarcomere dynamics for force transmission (32) as well as the availability of docking sites on the regulated thin filament (1, 38), key factors not retained in single-molecule studies. In addition, cooperative interactions between myosin motors and between motors and thin filament proteins (13, 18, 31, 33, 35) may strongly influence the collective output of the sarcomeric myosin motor array (reviewed in Ref. 8) . Given these considerations, data from intact muscle featuring intact excitation-contraction coupling and regulated thin filaments are required to answer fundamental questions regarding how striated muscle force is regulated at the myosin motor level.
Currently there is debate regarding how load-dependent variations in muscle force-velocity properties are regulated at the molecular level of the cross bridge. For example, experiments performed on single intact frog muscle fibers have provided evidence that the force-velocity properties may be achieved via variations in the number of cross bridges able to cycle against the thin filament or via alterations to the unitary properties of the individual cross bridges cycling against the thin filament. As an example, Piazzesi et al. (2007) used force and stiffness measurements to show that unitary force and displacement of individual cross bridges remained fixed (ϳ6 pN and ϳ6 nm, respectively) over a wide range of mechanical loads, thus supporting the idea that muscle force-velocity properties are determined by the number of cycling cross bridges able to contribute to work (23) . On the other hand, Reconditi et al. (2004) used X-ray interference to show that both the size and speed of the cross-bridge power stroke are reduced as mechanical load is increased, indicating that muscle force-velocity properties are determined via variations in the unitary properties of the myosin motor (27) . Results from experiments in which the number of cycling cross bridges is altered from within the intact working sarcomere may be able to resolve the pathway by which muscle force-velocity properties are regulated.
The purpose of this study was to determine whether the physiological performance of cardiac myocytes is influenced by a vector-mediated increase in motor domain-deleted "headless-myosin" expression. Our working hypothesis was that any alteration of the native two-headed myosin motor population, caused by headless-myosin incorporation into the cardiac sarcomere, would significantly compromise myocyte contractility. To this end we used virally mediated gene delivery (4, 5, 12, 19, 20, 40, 43) to express a motor domain-deleted headless-MHC in adult rat cardiac myocytes. Immunofluorescence and immunoprecipitation data demonstrated the expression of the headless-MHC and replacement of endogenous MHC from within the otherwise intact sarcomere of transduced myocytes. Modest to no effect of headless-MHC was observed on dynamic and steady-state contraction, suggesting a degree of tolerance for nonfunctional MHC molecules in striated muscle. Vector construction. The full-length human ␤-MHC cDNA [1,935 amino acids, nucleotide sequence, ϩ87 (ATG start) to 6,008 base pairs includes untranslated elements] was used as starting material (14) (a kind gift of Dr. Hans Vosberg). Because there is evidence that the myosin head-tail junction occurs at residue 900, the MHC was truncated at codon 900; accordingly, the truncated MHC extended from amino acid 900 to 1936, thus eliminating the entire motor domain (Fig. 1A) . We used PCR (35 cycles) to perform the truncation as follows. A 58-mer forward primer (5=-AAAGATATCATGGAC-TACAAAGACGATGACGACAAGGATGCTGAGGAGCGCTGT-GATC-3=) was generated containing a unique EcoRV site (indicated by italics), an NH2-terminal epitope Flag tag (DYKDDDDK) sequence, and MHC nucleotide sequence 2784 to 2809 (indicated by boldface). This was complemented with a 20-mer reverse primer (5=-GCTCCAGGGATCCTTCCAGA-3=) spanning a nucleotide position 3202 in ␤-MHC. The 454-bp PCR fragment was inserted into pCR2.1 (Invitrogen, Carlsbad, CA) by TA subcloning, and subsequently the ClaI-HindIII fragment of wild-type ␤-MHC was subcloned into the same vector. The DNA sequencing confirmed the correct ␤-MHC/headless sequence. With the 3,254-bp EcoRV and HindIII fragment from pCR2.1, ␤-MHC/headless was subcloned into adenovirus shuttle plasmid pPCA4 to generate recombinant adenovirus as described previously (14) . The insertion of an NH2-terminal epitope Flag tag at the truncation site enabled us to detect the presence of the headless-MHC by using an anti-Flag antibody. Amino acid primary sequence alignment between the headless human ␤-MHC and corresponding sequence (900 to COOH terminus) in rat ␣-MHC revealed 94% sequence identity (see Supplemental Fig. S1 ). 1 Myocyte isolation. Details regarding the myocyte isolation and virus delivery protocols have been presented in detail elsewhere (5, 12, 19, 20, 40, 43) . Briefly, rats were killed with an overdose of Nembutal, and the heart was quickly removed. Isolated hearts were suspended and perfused with digestion enzymes mixed in a Ca 2ϩ -free buffer solution. After the heart was taken down it was minced, and myocytes were mechanically isolated with custom-made pipettes. Single cells were subsequently plated onto laminin-coated coverslips and incubated in a medium containing DMEM ϩ 5% FBS. After 2 h, coverslips were incubated with the headless-MHC adenovirus [multiplicity of infection (MOI) ϭ 500] in serum-free medium for a 1-h period. After this the virus-containing medium was replaced with DMEM for overnight incubation. The next morning, coverslips (control ϩ transduced cells) were transferred to a custom-built stimulation chamber. Each well was filled with ϳ3 ml of M199 solution, and cells were stimulated at 0.2 Hz. Cells were subsequently harvested for Western blot analysis or immunohistochemistry at 24, 48, 72, or 96 h after gene transfer. Similarly, coverslips not used for Western analysis or immunohistochemistry were used for functional measurements at 24, 48, 72, and 96 h after gene transfer.
METHODS

All
Immunohistochemistry. Coverslips were fixed in 3% paraformaldehyde and washed in 50 mM NH4Cl in PBS. Each coverslip was blocked with 100 l of 20% normal goat serum in PBS ϩ 0.5% Triton X-100 for 30 min at room temperature. After the block was removed, coverslips were incubated with primary antibody in 200 l of 2% normal goat serum in PBS ϩ 0.5% Triton X-100 for 1.5 h at room temperature. Coverslips were washed in PBS ϩ 0.5% Triton X-100 and again blocked as described above. The block was removed, and coverslips were incubated with secondary antibody for 1 h at room temperature in 2% normal goat serum ϩ 0.5% Triton X-100. At this point some coverslips (single labeled) were washed in PBS and mounted on slides. Dual-labeled coverslips were washed in PBS ϩ 0.5% Triton X-100 and blocked with 1:20 goat anti-mouse IgG antibody in 2% normal goat serum in PBS ϩ 0.5% Triton X-100 at 4°C overnight. Coverslips were then washed in PBS ϩ 0.5% Triton X-100 and blocked with 1:20 goat anti-mouse Fab fragments in 2% normal goat serum in PBS ϩ 0.5% Triton X-100 for 1.5 h at room temperature. Coverslips were washed in PBS ϩ 0.5% Triton X-100 and blocked with 20% normal goat serum in PBS ϩ 0.5% Triton X-100. The block was removed, and the coverslips were incubated in the second primary antibody diluted in 2% normal goat serum in PBS ϩ 0.5% Triton X-100 for 1.5 h at room temperature. Coverslips were washed in PBS ϩ 0.5% Triton X-100 and then blocked with 20% normal goat serum in PBS ϩ 0.5% Triton X-100. The block was removed, and coverslips were incubated in the second secondary antibody for 1 h at room temperature in 2% normal goat serum in PBS ϩ 0.5% Triton X-100. Coverslips were washed in PBS and mounted on slides. The primary and secondary antibodies used (with dilutions) were 1) anti-Flag M2 (1:500), 2) ␣-actinin EA53 (1:500), and 3) goat anti-mouse conjugated to Texas red (1:100) and goat anti-mouse conjugated to FITC (1:200) .
SDS PAGE and Western blotting. Commercially available antibodies were used to probe Western blots to quantify relative protein content in myocytes. Myocyte samples were obtained by scraping coverslips for standard SDS gel electrophoresis (12% running gel; 3.5% stacking gel), after which proteins were transferred to a nitrocellulose membrane. Membranes were subsequently probed by using a variety of monoclonal antibodies to detect and quantify headless-MHC and endogenous MHC content in both control and transduced myocytes. The anti-Flag M2 antibody (Sigma-Aldrich, St. Louis, MO) was used for specific detection of the headless-MHC construct. The 805-501 antibody (Hybridoma Lab, University of Iowa) was used for specific detection of the native endogenous MHC. In addition, actin content was quantified with the 5C5 monoclonal antibody (SigmaAldrich). Finally, the MF-20 antibody (Hybridoma Lab, University of Iowa), which reacts with the rod portion of the native MHC, was used to detect both the endogenous and the headless-MHC in the same blots.
Immuno-coprecipitation experiments were performed to determine whether a population of single-headed myosin heterodimer molecules was generated by the dimerization of the endogenous MHC with the headless-MHC transgene product. To do this, transduced and control myocytes were collected 96 h after cell dissociation, when headless-MHC expression was maximal in transduced myocytes. Transduced and control myocytes were obtained by combining six coverslips (ϳ1.2 ϫ 10 5 cells) together, after which they were treated with a lysis buffer containing HEPES (40 mmol/l), NaCl (120 mmol/l), EDTA (1 mmol/l), sodium pyrophosphate (1 mmol/l), glycerol 2-phosphate (1 mmol/l), sodium fluoride (5 mmol/l), sodium orthovanadate (1.5 mmol/l), and 0.30% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) detergent. Samples were then rocked in a lysis buffer for 20 min at 4°C and subsequently centrifuged (1,000 g) for 3 min. The supernatant used for coprecipitation was collected after high-speed spin and before addition of the primary antibody. Overnight immunoprecipitation of the supernatant or pellet fraction (150 g total protein) with the BA-G5 (mouse monoclonal BA-G5; American Type Culture Collection) antibody was performed overnight at 4°C. The next day each sample was treated with an excess amount of goat anti-mouse IgG magnetic beads (BioMag, Fishers, IN) for 1 h to immunoprecipitate the BA-G5 antibody and any associated proteins. The protein sample was subsequently washed twice in the lysis buffer and finally eluted in SDS sample buffer for electrophoresis and Western blotting. Immunoprecipitated samples were then probed with the anti-Flag M2 monoclonal antibody to determine whether the headless-MHC associated with the endogenous MHC. Additionally, the MF-20 antibody was used to probe for endogenous and headless myosin. These coprecipitation experiments were performed on cells obtained from two separate cardiac myocyte isolations that each consisted of separate control and transduced cells. A single coprecipitation procedure was performed on cells from each experiment.
Mechanical measurements on membrane-intact myocytes. Sarcomere shortening amplitudes of control (Ϫvirus) and transduced (ϩvirus) myocytes were determined on each day after cell dissociation. All measurements were made with the IonOptix imaging/data collection system (Milton, MA). For these measurements myocyte-containing coverslips were placed on a custom-made chamber located on the stage of a Nikon epifluorescence microscope fitted with a ϫ40 water immersion objective. After coverslip mounting the chamber was filled with M199 solution; field stimulation of myocytes was achieved via platinum electrodes embedded within the chamber. A Grass S88 stimulator was used to elicit twitch shortening at a frequency of 0.2 Hz (30 -40 V). A charge-coupled device (CCD) video camera was used to capture real-time images of myocyte shortening. IonOptix proprietary software converted images of myocyte sarcomere striation patterns into a sarcomere length value in micrometers. Changes in sarcomere striation spacing during each twitch contraction were presented graphically. Several of these individual tracings were averaged to calculate sarcomere shortening amplitude. Ca 2ϩ measurements. The amplitude and kinetics of the intracellular calcium transient (ICT) triggering twitch shortening of transduced and control myocytes were quantified with the membrane-permeant form of the ratiometric fluorescent indicator fura-2 (Molecular Probes, Eugene, OR). Experiments were performed at 24 and 96 h after cell dissociation, times corresponding to normal and impaired contractility of transduced myocytes, respectively. Myocytes were prepared and mounted on the IonOptix system as described above with the exception that, before measurements, myocytes were exposed to M199 containing a 1 M concentration of the dye. The fluorescenceimaging capability of the IonOptix system was used to obtain a fura-2-based-ratiometric fluorescence (excitation at 360 and 380 nm) signal simultaneous with shortening. After subtraction of the background fluorescence at each wavelength, the ratio signals from all myocytes were converted to an intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) with the formula [Ca 2ϩ ] ϭ Kd·(R Ϫ Rmin)/(Rmax Ϫ R)·␤, where Rmin is the fura-2 ratio signal representing 0 calcium and Rmax is the fura-2 ratio signal representing saturating calcium levels (10) . Values for R min and Rmax were obtained during a calibration procedure using intact myocytes exposed to zero and saturating [Ca 2ϩ ] levels, respectively. The ␤ term represents the ratio of emitted fluorescence in response to excitation at 380-nm light while myocytes were incubated in R min and Rmax solutions. A Kd value of 225 nM was assumed. Because fura-2 is a high-affinity chelator (10) , it thus competes with troponin C for Ca 2ϩ . Although great care was taken to standardize cell loading and minimize this effect, any myocyte exhibiting abnormal or no sarcomere shortening was included in the ICT analysis.
Membrane-permeabilized myocytes. The maximal Ca 2ϩ -activated isometric tension and the [Ca 2ϩ ] required for 50% force development (pCa 50 2ϩ ) of transduced and control myocytes were measured at 24 and 96 h after cell dissociation, times corresponding to low and high levels for headless-MHC content, respectively. See Metzger (18) for details regarding the myocyte model used in these studies.
Statistical analysis. A two-way analysis of variance (ANOVA) with Tukey's post hoc test was performed to determine differences in mechanical parameters between conditions at the different time points examined in this study (P Ͻ 0.05). In addition, a t-test was used to test for differences in the ICT characteristics of membrane-intact myocytes as well in steady-state tension responses of permeabilized myocytes at 96 h after cell dissociation (P Ͻ 0.05).
RESULTS
Headless-MHC expression.
Headless-MHC expression in transduced myocytes relative to actin (left) or endogenous MHC (right) over the course of the experiment is plotted in Fig. 1B . Both plots show minimal expression of the headless-MHC at 24 h after gene transfer and a severalfold increase thereafter. Total sarcomeric actin levels remained constant over this time period in both control and transduced myocytes (data not shown). As shown in Fig. 1 , B and C, although headless-MHC was detected in transduced myocytes, no headless-MHC expression was detected in control myocytes at any time point. A summary of blots probed with the MF-20 antibody in Fig. 1C details how headless-MHC (top), endogenous MHC (middle), and total MHC (i.e., headless ϩ endogenous; bottom) expression changed in transduced myocytes over time. This figure shows the increase in headless-MHC expression from 24 to 96 h after gene transfer and the corresponding decrease in endogenous-MHC over this time. Headless-MHC accounted for ϳ20% of the total MHC of transduced myocytes 96 h after gene transfer. Because endogenous MHC showed a corresponding decrease, there were no significant changes in total MHC during this experiment. This coupling of headless-MHC to endogenous MHC expression is presumably related to the turnover rate of endogenous MHC (17) . These findings are evidence of preserved MHC stoichiometry as has been documented for other sarcomeric proteins upon gene transfer or transgenesis (19) .
Headless-MHC sarcomeric incorporation. Figure 2 displays confocal images taken from control and transduced myocytes showing sarcomeric localization of the headless-MHC. Figure  2A shows a low-power view of transduced myocytes labeled with anti-Flag antibody revealing the high efficiency of the gene transfer technique (Ͼ95% expressed headless-MHC). Figure 2B (middle) shows the striated pattern of headless-MHC and provides evidence that headless-MHC is distributed homogeneously along the entire length and width of the myocyte and properly incorporated within the cardiac sarcomere Aband. Figure 2 , C, left, middle, and right, are anti-Flag and anti-␣-actinin images that provide further evidence of the correct thick filament localization of headless-MHC in the sarcomere. Figure 2D shows electron micrographs of a transduced myocyte taken 96 h after gene transfer and reveals no evident ultrastructural defects due to headless-MHC incorporation in the sarcomere.
Coexpression of endogenous and headless-myosin. We used immuno-coprecipitation to test whether headless-MHC expressed in transduced myocytes was associated with endogenous full-length MHC. These experiments utilized the BA-G5 antibody, which is specific for the globular head of ␣-MHC and thus detects endogenous MHC. Western blots shown in Fig. 3 provide evidence of heterodimers formed by headless-MHC and endogenous MHC in transduced myocytes. After BA-G5 immunoprecipitation, headless-MHC was detected with anti-Flag antibody (Fig. 3A) and separately with MF-20 antibody (Fig. 3B) . Detection of both headless-MHC and endogenous MHC in the pellet fraction shown in Fig. 3B (lane 1) suggests at least some amount of headless-MHC and endogenous MHC heterodimer formation in the transduced myocytes. Whereas the data support a conclusion of at least some heterodimer formation, quantitative assessment of percent homodimer versus percent heterodimer is not defined in these experiments.
Myocyte shortening. Absolute data for mechanical performance of membrane-intact control (nontransduced) and transduced myocytes at 24, 48, 72 and 96 h after cell dissociation and gene transfer are compiled in Table 1 , while example traces and relative shortening data are summarized in Fig. 4 . Both control and transduced myocytes displayed a slight, time-dependent increase in shortening amplitude (and associated parameters) over the first 72 h of observation. The shortening amplitude data for control myocytes at 96 h after gene transfer reported here are similar to data previously reported from this lab at day 4 in primary culture (4, 43) . Most parameters of contractile performance of transduced myocytes did not differ from control myocytes during the initial 72 h after cell dissociation, a time when headless-MHC expression was increasing in the transduced myocytes. On the other hand, both sarcomere shortening amplitude and sarcomere shortening speed of transduced cells were attenuated by 16 Ϯ 4% and 17 Ϯ 4% compared with control cells by 96 h after cell dissociation (P Ͻ 0.05). In addition, the speed of sarcomere shortening and relengthening was reduced by 26 Ϯ 6% in transduced compared with control cells at this time point (P Ͻ 0.05). Ca 2ϩ transients. Representative traces and summary data for experiments quantifying the ICT of control and transduced myocytes at 96 h are shown in Fig. 5 . These data show that neither the amplitude nor the duration of the ICT measured from transduced myocytes was attenuated compared with control myocytes at 96 h after cell dissociation. For example, in relative terms, the resting [Ca 2ϩ ] i and ICT amplitude of transduced myocytes were 0.95 Ϯ 0.12 and 1.24 Ϯ 0.13 times that determined for control myocytes, respectively (Fig. 5B) . Moreover, the duration of the ICT displayed by transduced myocytes was similar to that observed in control myocytes (i.e., 1.03 Ϯ 0.05 times that in control myocytes).
Controls. In a separate study, adult rat cardiac myocytes were transduced with a vector harboring a LacZ gene reporter cassette. Expression of ␤-galactosidase was verified by staining (Ͼ95% myocytes expressing), and the shortening amplitude of LacZ myocytes was similar to control myocytes at 24, 48, and 96 h after gene transfer (data not shown). Thus, consistent with previous results from this laboratory (19, 20) , control experiments indicate that gene transfer per se did not influence myocyte contractility.
Chemically permeabilized myocytes. In addition to intact myocyte studies, experiments were performed on chemically permeabilized myocytes to determine the effect of headless-MHC on steady-state aspects of tension development ( Table 2 ). The data show no significant alterations in steady-state tension development in myocytes expressing the headless-MHC. Neither the F max nor the pCa 50 2ϩ of transduced myocytes was altered relative to control myocytes when measured at 96 h.
DISCUSSION
Acute genetic engineering of myosin motors in living myocytes would represent a valuable adjunct to single-motor molecular biophysical studies. We report that a headless-MHC construct can efficiently express and incorporate into the sarcomere of living myocytes in culture, replacing ϳ20% of native myosin and leaving total myosin (headless ϩ normal) unchanged. Because total myosin content remained constant while headless-MHC increased, this is evidence of stoichiometric replacement of native MHC by headless-MHC. Headless-MHC did not markedly affect dynamic or steady-state performance. These results suggest that living myocytes can tolerate a moderate population of non-mechanoenzyme-competent myosin molecules. The data further suggest that the mechanism for this outcome may include variations in cross-bridge mechanical properties as proposed by Reconditi et al. (27) .
Previous studies have shown that intact rat cardiac myocytes remain viable, and allow study of mechanical and chemical properties, for several days in primary culture (4, 12) . Indeed, in our hands, sarcomere shortening amplitude was robust throughout the 96 h of the primary culture period, indicating the fidelity of this experimental model. The great advantage of studying contractile behavior of membrane-intact myocytes is that the motor ability of the myosin array can be assessed in response to a physiologically intact excitation-contraction coupling pathway. Here, in response to field stimulation, the contractile system is activated by transient elevations in [Ca 2ϩ ] at a physiological temperature of 37°C. In addition, the intact myocyte incorporates all biologically relevant activation-and cooperativity-dependent processes that may be missing from other more simplified model systems. Expression and incorporation of the headless-MHC mutant thus permitted study of the influence of altered myosin motor population on contractile function in the context of physiologically relevant factors such in A and B blots) . These gels are included to show that, in addition to the MHC, lower-molecular-mass proteins of undetermined identity are also pulled down by BA-G5 antibody. as temperature, myofilament lattice spacing, Ca 2ϩ activation, and myofilament cooperativity. If it were possible to extend primary culture time to permit even greater replacement of endogenous MHC with headless-MHC, more produced deficits in contractility might have been obtained than reported here.
Headless-myosin expression and incorporation. Immunofluorescence data provide evidence that the headless-MHC was properly incorporated into the cardiac sarcomere of transduced myocytes. Moreover, the immunoprecipitation data indicate that headless-MHC dimerized, at least to some extent, with endogenous MHC already present on the thick filament. Because there was a corresponding decrease in endogenous MHC expression coincident with headless-MHC it is likely that the sarcomere of the transduced cardiac myocyte contained a population of single-headed dimeric MHC motor molecules. Because the headless-MHC construct contained the entire COOH-terminal rod domain, the most important domain for heavy chain assembly into the thick filament (22, 29, 30) , motor domain truncation should not have impaired the ability of headless-MHC to dimerize with endogenous MHC and assemble into the thick filament. In this regard, the observation that headless-MHC expression was greatest 72-96 h after gene delivery while modest contractile deficits were observed at only at 96 h may relate to turnover rate for endogenous MHC (17) delaying actual replacement of endogenous MHC with headless-MHC relative.
Relation to models for force regulation. Our results from chemically permeabilized and membrane-intact cardiac myocytes may be interpreted in terms of current models of force regulation. For example, unchanged steady-state (isometric) force-pCa responses between chemically permeabilized transduced and control myocytes indicates that thin filament activation, and not cross-bridge availability per se, regulates contractility at both low and high levels of Ca 2ϩ activation. This is possible if, consistent with the results of Reconditi et al. (27) , reductions in myosin motor number available for binding to the thin filament are compensated for by increases in the force exerted per strongly bound cross bridge. Our results from membrane-intact myocytes during dynamic twitch contractions are consistent with the idea that cross-bridge mechanical output is variable. As an example, the similarity in sarcomere shortening amplitude of transduced and control myocytes observed over the first 3 days of primary culture suggests that crossbridge force and/or displacement may increase commensurate with a reduction in myosin motor number available for binding to the thin filament. Cross-bridge cycling during dynamic shortening of intact myocytes in response to rapid and brief Ca 2ϩ transients poses limitations on the ability of individual cross bridges to increase unitary force and/or displacement and compensate for reductions in myosin motor number. In contrast, cross-bridge cycling during isometric force development of permeabilized myocytes, in response to steady-state Ca 2ϩ activation (submaximal or saturating), may allow for relatively greater variations in cross-bridge output that compensate for reductions in functional dimeric myosin motors in the cardiac sarcomere.
Limitations. The main purpose of these experiments was to develop an experimental system to study how myosin motor manipulation influences contractility of intact myocytes. One limitation of this work centers on uncertainties regarding the precise nature of the replacement of endogenous MHC with headless-MHC in the thick filament of the transduced myocytes. Thus conclusions regarding headless-MHC incorporation into the thick filament are limited by uncertainties of the exact amount of homodimer versus heterodimer formation between headless-MHC and endogenous MHC. The immunolabeling and confocal imaging findings do, however, provide evidence that headless myosin was correctly positioned in the A band of the sarcomere. Finally, although there is 94% homology between human and rat MHC sequence (Supplemental Fig. S1 ), we cannot entirely exclude the possibility that differences in sequence between human and rat MHC complicated our results.
Summary. We tested the effects of headless-MHC on cardiac myocyte function. Expression and incorporation of headless-MHC in the cardiac sarcomere modestly attenuated myocyte shortening under conditions of transient, but not steady-state, Ca 2ϩ activation. These results show that a full complement of dimeric myosin motors is required for full dynamic function of membrane-intact cardiac myocytes under physiological conditions. The results can also be interpreted to indicate that as many as ϳ20% dysfunctional myosin molecules in the sarcomere can have modest to no effects on contractility, indicating an apparent safety factor of functional myosin molecules in cardiac muscle. In this regard, our results support the idea that unitary properties of the cycling cross-bridge power stroke, and not cross-bridge number, are a critical parameter influencing mechanical performance.
